Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Gordon B. Mills(The University of Texas MD Anderson Cancer Center), Allison Creason(Oregon Health & Science University), Anca Chelariu-Raicu(Ludwig-Maximilians-Universität München), Robert L. Coleman(Texas Oncology), Christopher P. Vellano(The University of Texas MD Anderson Cancer Center), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center), Yong Fang(Oregon Health & Science University), Aurora Blucher(Oregon Health & Science University), Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Pamela T. Soliman(The University of Texas MD Anderson Cancer Center), Marilyne Labrie(Université de Sherbrooke), Joseph R. Marszalek(The University of Texas MD Anderson Cancer Center), Ningping Feng(The University of Texas MD Anderson Cancer Center), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Michael Frumovitz(The University of Texas MD Anderson Cancer Center), Charlotte C. Sun(The University of Texas MD Anderson Cancer Center), Tae‐Beom Kim(The University of Texas MD Anderson Cancer Center), Sanghoon Lee(The University of Texas MD Anderson Cancer Center), Jinsong Liu(Guangzhou Institutes of Biomedicine and Health), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Xiaoyan Ma(Shanghai East Hospital), Nashwa Kabil(AstraZeneca (Japan)), Tsun Hsuan Chen(The University of Texas MD Anderson Cancer Center), Larissa A. Meyer, Katheleen M. Schmeler(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center)
Clinical Cancer Research
September 13, 2021
Cited by 76


Related Papers